Cargando…
Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains an effective option for the treatment of intermediate and high-risk Acute myeloid leukemia (AML). Post-transplant lymphoproliferative disorder (PTLD) is related to the intensity of post-transplant immunosuppression. Although Epst...
Autores principales: | Yiğit Kaya, Süreyya, Askin, Abdullah Emre, Bektas, Sebnem, Çakır, Aslı, Gökmen Sevindik, Ömür |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195982/ https://www.ncbi.nlm.nih.gov/pubmed/37213444 http://dx.doi.org/10.1016/j.lrr.2023.100369 |
Ejemplares similares
-
Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case
por: Mutlu, Yasa Gul, et al.
Publicado: (2023) -
Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data
por: Karakus, Volkan, et al.
Publicado: (2022) -
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012) -
Should Core Needle Lymph Node Biopsy be a Relevant Alternative to Surgical Excisional Biopsy in Diagnostic Work Up of Lymphomas?
por: Gül Mutlu, Yaşa, et al.
Publicado: (2023) -
Predictive value of stathmin-1 and osteopontin expression for taxan resistance in metastatic castrate-resistant prostate cancer
por: Aksoy, Asude, et al.
Publicado: (2017)